Skip to search formSkip to main contentSkip to account menu

Brigatinib

Known as: (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone 
An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

AP26113
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Brigatinib Outperforms Crizotinib as First-Line Therapy.
The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in… 
2019
2019
ALK disease: best first or later, and do we care about variants?
The therapeutic landscape in advanced ALK + non-small cell lung cancer (NSCLC) is rapidly evolving due to the increasing… 
2018
2018
Hplc-Ms / Ms Method Development And Validation For Determining Stability of Brigatinib In Human Plasma Samples
The validated protein precipitation method was applied for estimation of brigatinib in human plasma with brigatinib-D6 as an… 
2017
2017
Brigatinib Approved, but Treatment Role Uncertain.
The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take… 
Review
2017
Review
2017
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC : Which ALK TKI to Use Upfront ?
Introduction The identification of the EML4-ALK fusion oncogene in 2007 as a driver of pathogenesis, in the 2% to 7% of patients… 
2017
2017
Brigatinib Achieves Whole-Body and Intracranial Responses.
Brigatinib is tolerable and has antitumor activity in crizotinib-resistant ALK-positive NSCLC. 
2017
2017
1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS…
2017
2017
Brigatinib bei ALK-positivem NSCLC
Die meisten mit Crizotinib behandelten Patienten mit ALK-positivem NSCLC erleiden in absehbarer Zeit ein Rezidiv. In dieser… 
2016
2016
Brigatinib Shows Promise in ALK-Positive NSCLC After Crizotinib Therapy
The TKI brigatinib offered good response rates in a phase II trial of patients with ALK-positive non–small-cell lung cancer whose… 
2016
2016
Brigatinib Trial Taking Place for ALK-Positive NSCLC Patients
Virginia Cancer Specialists reported they have enrolled the first patient in a new advanced lung cancer clinical trial for…